People · Operator
Named in public records as an officer, director or promoter · active 2012–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cytonus Therapeutics, Inc. | — | Biotechnology | Series A | $14.3M | $85.3M | 2021 |
| Endosphere, Inc. | — | Biotechnology | Seed | $6.5M | $88.8M | 2012 |
Christopher Thorne at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Thorne on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick O'Donnell | 1 | 6 |
| John R. Lyon | 1 | 2 |
| Richard Klemke | 1 | 1 |
| Jae An | 1 | 1 |
| Manisha Narasimhan | 1 | 1 |
| Remo Moomiaie | 1 | 1 |
| James McKinley | 1 | 1 |
| John R Huston | 1 | 1 |
| Ajit R Thakur | 1 | 1 |
| Christopher R Thorne | 1 | 1 |
| James T McKinley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.